title: A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic vivid p450 substrate.
abstract: Large-scale screening of multiple compound libraries and combinatorial libraries for pharmacological activity is one of the novel approaches of the modern drug discovery process. The application of isozyme-specific high-throughput screening (HTS) assays for characterizing the interactions of potential drug candidates with major human drug-metabolizing cytochrome p450 enzymes (p450s) is newly becoming an essential part of this process. Fluorescence-based HTS assays have been successfully employed for in vitro assessment of drug-drug interactions and enzyme inhibition with several p450 isoforms, including CYP3A4, CYP2D6, CYP2C9, and CYP2C19. Here we describe a fluorescence-based HTS assay for detecting drug metabolism and inhibition with human CYP2E1. CYP2E1 plays an important role in the metabolism of several drugs, many solvents, and toxins and therefore has been repeatedly linked to numerous pathologies, including cancer, liver and kidney toxicity, diabetes, and alcoholism. The assay is based on the ability of a drug to compete with the fluorogenic Vivid CYP2E1 Blue Substrate for CYP2E1 metabolism and thus enables rapid screening of lead molecules for their inhibitory potential. We have used this assay to screen a panel of drugs and compounds for their effects on CYP2E1 metabolism and inhibition. Our results demonstrate the assay's usefulness in identifying CYP2E1 substrates and inhibitors and in enabling in-depth characterization of their interactions with the CYP2E1 isozyme. We also present detailed characteristics of the assay, including its dynamic range and Z'-factor values, which indicate that this robust assay is well suited for kinetic and inhibition studies in HTS formats.
authors.affiliation: Pan Vera LLC, Madison, WI, USA.
authors.forename: Bryan D
authors.initials: BD
authors.lastname: Marks
authors.forename: Ronald W
authors.initials: RW
authors.lastname: Smith
authors.forename: Heidi A
authors.initials: HA
authors.lastname: Braun
authors.forename: Tony A
authors.initials: TA
authors.lastname: Goossens
authors.forename: Marie
authors.initials: M
authors.lastname: Christenson
authors.forename: Mary S
authors.initials: MS
authors.lastname: Ozers
authors.forename: Connie S
authors.initials: CS
authors.lastname: Lebakken
authors.forename: Olga V
authors.initials: OV
authors.lastname: Trubetskoy
mesh_terms: D016367:Baculoviridae / Q000235:genetics; D002478:Cells, Cultured; D019392:Cytochrome P-450 CYP2E1 / Q000378:metabolism*; D065691:Cytochrome P-450 CYP2E1 Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D004353:Drug Evaluation, Preclinical; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005456:Fluorescent Dyes; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000378:metabolism; D007700:Kinetics; D008861:Microsomes / Q000187:drug effects / Q000201:enzymology; D012997:Solvents / Q000494:pharmacology; D013050:Spectrometry, Fluorescence
chemical_list: D065691:Cytochrome P-450 CYP2E1 Inhibitors; D004791:Enzyme Inhibitors; D005456:Fluorescent Dyes; D007527:Isoenzymes; D012997:Solvents; D003577:Cytochrome P-450 Enzyme System; D019392:Cytochrome P-450 CYP2E1